Locations
European law firm Fieldfisher’s Life Sciences team has advised Adtec Healthcare Limited, a pioneering company in Cold Plasma medical technology, on its successful $12 million funding round.
This strategic investment will enable Adtec to expand its global footprint and enter the U.S. market, marking a significant milestone in the company’s growth journey. The funding will also support the development of a next-generation Cold Plasma medical device, bringing Adtec a step closer to its vision: to make Cold Plasma a globally recognised and adopted standard in infection control and wound care.
The funding round attracted international investors from Taiwan and the United States, and the team at Fieldfisher stepped in to provide additional support beyond the typical scope of engagement, ensuring a smooth and efficient transaction.
Don't miss a thing, subscribe today!
Stay up to date by subscribing to the latest Life Sciences insights from the experts at Fieldfisher.
Subscribe nowThe Fieldfisher team was led by Janita Good, Partner, Dana French, Senior Associate and Alexandra Basford, Solicitor. Their combined expertise and commitment played a key role in delivering a successful outcome for Adtec Healthcare.
Janita said: "We’re proud to have supported Adtec Healthcare on this pivotal funding round, which marks an exciting step in their global growth journey. The cross-border nature of the investment, collaborating across time zones and navigating a unique investor landscape made this a particularly rewarding transaction. We look forward to seeing their continued success in the U.S. and beyond."
Mary McGovern, CEO of Adtec Healthcare, praised Fieldfisher for the team's dedication to understanding the business, saying: "Having worked with Fieldfisher previously on our company spinout from a global industrial plasma company, we knew that the team understood the vision we have at Adtec, and had a deep understanding of the opportunities this investment would have on bringing that vision to life. We thank the team for their hard work and expertise."
This deal reinforces Fieldfisher’s strong track record in the Life Sciences sector, where the firm continues to support innovative companies at the forefront of medical technology. It also builds on Fieldfisher’s longstanding relationship with Adtec Healthcare, having previously advised on their corporate spin out in 2023.
